Get the Daily Brief
Latest Biotech News
Regulatory approvals: vaccines and oncology clearances
FDA cleared Moderna’s mRNA flu vaccine mFLUSIVA (mRNA-1010) for adults 50–64 and 65+, marking the first US approval of a seasonal flu shot built on mRNA. The path included a refusal-to-file...
Clinical trial and early efficacy signals: targeted immunology and cell-based approaches
A Boston Children’s Hospital Phase I study reported that oral encapsulated fecal microbiome transplantation (FMT) was feasible and may increase peanut tolerance in adults with severe peanut...
Drug development in ophthalmology: large deals and late-stage asset moves
Tarsus Pharmaceuticals announced it will acquire Alkeus Pharmaceuticals for up to $800 million, including ownership of ALK-001 (gildeuretinol), a once-daily, Phase 3-stage therapy for Stargardt...
Biotech IPOs: new listings to fund clinical catalysts
Attovia Therapeutics priced an upsized IPO at $289 million (sold 17 million shares at $17 each), putting the proceeds toward two planned Phase II trials in 2027 for ATTO-1310, an engineered...
Oncology drug delivery: radiopharmaceutical trial strategy advances earlier use
Weill Cornell Medicine and partner institutions reported Phase 3 results from PSMAddition showing that adding a targeted radiopharmaceutical earlier in the metastatic prostate cancer care pathway...
M&A and portfolio reshaping: platform and asset acquisitions
Arrowhead Pharmaceuticals struck a $215 million deal to acquire PRV, according to a filing referenced in the deal coverage, signaling continued consolidation around precision immunology and...
Funding and venture: new financing rounds to push clinic-ready programs
Expedition Therapeutics raised $115 million in a Series B led by General Atlantic to advance EXPD-101, a once-daily, orally administered program targeting neutrophilic inflammation via DPP1...
Platform innovation: molecular glue degraders and next-generation targeted degradation
Dana-Farber Cancer Institute researchers reported the development of a systematic platform for discovering molecular-glue degraders, aimed at redirecting a cell’s protein-disposal machinery toward...
AI-enabled clinical operations: trial delivery automation
Icon announced a multi-year collaboration with Anthropic to deploy Claude across clinical trial workflows, targeting a persistent bottleneck in drug development: site intelligence, enrollment...
Transplant and immunology: outcome-linked policy models for gene therapy access
A viewpoint in the Journal of Managed Care & Specialty Pharmacy reviewed the CMS Cell and Gene Therapy (CGT) Access Model for sickle cell disease, describing the payment framework and identifying...
FDA approvals: oncology and vaccines
The FDA granted Replimune accelerated approval for its engineered oncolytic-virus therapy Tudriqev (formerly RP1) in advanced melanoma, ending a two-time rejection saga. The treatment was cleared...
Moderna’s mRNA flu vaccine: regulatory turnaround
The FDA approved Moderna’s mRNA seasonal influenza vaccine, mFlusiva (mRNA-1010), marking the first U.S. licensed flu shot built on mRNA technology. The approval covers adults at least 50 years...
Ophthalmology M&A: Tarsus acquires Alkeus for Stargardt asset
Tarsus Pharmaceuticals agreed to acquire Alkeus Pharmaceuticals for up to $800 million, securing ownership of Alkeus’s once-daily oral candidate ALK-001 (gildeuretinol) for Stargardt disease. The...
Immuno-oncology pipeline: engineered oncolytic therapy approval and viral vector immunobiology
Beyond the Replimune clearance, the broader oncology pipeline remains active on viral immunotherapy and tumor microenvironment reprogramming. In parallel peer-reviewed research, engineered...
Biotech funding and IPOs: cash for late-stage and platform bets
Several biotechs pushed into or expanded public markets, providing fresh capital for clinical de-risking and pipeline buildouts. Attovia priced an upsized IPO reported at roughly $289–$298 million...
Biotech funding: Expedition’s COPD Series B and platform push
Expedition Therapeutics closed a $115 million Series B led by General Atlantic as it progresses EXPD-101, an orally dosed candidate designed to target neutrophilic inflammation in COPD. The...
Gene editing and cell therapy risks: China DMD death and clinical transparency concerns
A new reported death tied to gene editing in China highlights ongoing safety and transparency questions. Coverage describes a disclosed fatality involving Huidagene Therapeutics’s HG-302 gene...
Diagnostics and MRD: new regulatory submissions in bladder cancer
Natera submitted its Signatera molecular residual disease assay to Japan’s PMDA as a companion diagnostic for Tecentriq (atezolizumab) in muscle-invasive bladder cancer. The submission leverages...
Alzheimer’s mechanisms and biomarkers: tau enters mitochondria and pTau217 expands populations
Two tau-focused developments moved the Alzheimer’s field forward on both mechanism and measurement. In preclinical work led by Stanford Medicine, chemically modified tau was reported to enter...
Genomics reference and immunology design: telomere-to-telomere consortium expands benchmarking
The Telomere-to-Telomere (T2T) Consortium published complete diploid human genome data using reference-assembly approaches, creating a higher-resolution baseline for variant detection and disease...